Lymphoproliferation and hyper-IgM as the first manifestation of activated phosphoinositide 3-kinase δ syndrome: A case report

Mónica Fernandes-Pineda , Andrés F. Zea-Vera, .

Keywords: immune system diseases, phosphatidylinositol 3-kinase, hyper-IgM immunodeficiency syndrome, autoimmunity, human genetics, genetic testing

Abstract

Activated phosphoinositide 3-kinase δ syndrome is an inborn error of immunity due to mutations within the genes responsible for encoding PI3Kδ subunits. This syndrome results in an excessive activation of the phosphoinositide 3-kinase signaling pathway. Gainof-function mutations in the gene PIK3R1 (encoding p85α, p55α, and p50α) lead to the development of the activated PI3K δ syndrome. Notably, the clinical presentations of this syndrome often closely resemble those of other primary immunodeficiencies.
We present a case involving a 15-year-old male who displayed an immunological phenotype that bore a striking resemblance to hyper-IgM syndrome. Whole exome
sequencing was undertaken to pinpoint the underlying genetic mutation.
Our investigation successfully identified a heterozygous splice site mutation previously reported within the well-established hotspot of the PIK3R1 gene (GRCh37, c.1425+1 G>T). The diverse spectrum of inborn errors of immunity underscores the pivotal role of identifying gene mutations, particularly in patients presenting clinical manifestations spanning autoimmune disorders, lymphoproliferative conditions, and antibody deficiencies. Such precise genetic diagnoses hold significant potential for improving patient care and management.

Downloads

Download data is not yet available.
  • Mónica Fernandes-Pineda Departamento de Medicina Interna, Universidad del Valle, Cali, Colombia https://orcid.org/0000-0003-4891-543X
  • Andrés F. Zea-Vera Departamento de Microbiología, Facultad de Salud, Universidad del Valle, Cali, Colombia; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disorders, National Institutes of Health, Bethesda, MD, USA https://orcid.org/0000-0001-9127-3677

References

Nguyen T, Lau A, Bier J, Cooke KC, Lenthall H, Ruiz-Diaz S, et al. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2. J Exp Med. 2023;220:e20221020. https://doi.org/10.1084/jem.20221020

Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominantactivating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15:88-97. https://doi.org/10.1038/ni.2771

Singh A, Joshi V, Jindal AK, Mathew B, Rawat A. An updated review on activated PI3 kinase delta syndrome (APDS). Genes Dis. 2020;7:67-74. https://doi.org/10.1016/j.gendis.2019.09.015

Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3:317-30. https://doi.org/10.1038/nri1056

Redenbaugh V, Coulter T. Disorders related to PI3Kδ hyperactivation: Characterizing the clinical and immunological features of activated PI3-kinase delta syndromes. Front Pediatr. 2021;9. https://doi.org/10.3389/fped.2021.702872

Yazdani R, Hamidi Z, Babaha F, Azizi G, Fekrvand S, Abolhassani H, et al. PIK3R1 mutation associated with hyper IgM (APDS2 syndrome): A case report and review of the literature. Endocr Metab Immune Disord Drug Targets. 2019;19:941-58. https://doi.org/10.2174/1871530319666190225114739

Condliffe AM, Chandra A. respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome. Front Immunol. 2018;9. https://doi.org/10.3389/fimmu.2018.00338

Durandy A, Kracker S. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma. Blood. 2020;135:638-43. https://doi.org/10.1182/blood.2019002072

Jamee M, Moniri S, Zaki-Dizaji M, Olbrich P, Yazdani R, Jadidi-Niaragh F, et al. Clinical, immunological, and genetic features in patients with activated PI3Kδ syndrome (APDS): A systematic review. Clin Rev Allergy Immunol. 2020;59:323-33. https://doi.org/10.1007/s12016-019-08738-9

Lucas CL, Zhang Y, Venida A, Wang Y, Hughes J, McElwee J, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211:2537-47. https://doi.org/10.1084/jem.20141759

Lougaris V, Faletra F, Lanzi G, Vozzi D, Marcuzzi A, Valencic E, et al. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. Clin Immunol. 2015;159:33-6. https://doi.org/10.1016/j.clim.2015.04.014

Ewertowska M, Grześk E, Urbańczyk A, Dąbrowska A, Bąbol-Pokora K, Łęcka M, et al. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): Similarities and differences based on clinical presentation in two boys. Allergy Asthma Clin Immunol. 2020;16:22. https://doi.org/10.1186/s13223-020-00420-6

Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42:1508-20. https://doi.org/10.1007/s10875-022-01352-z

Maccari ME, Wolkewitz M, Schwab C, Lorenzini T, Leiding JW, Aladjdi N, et al. Activated Phosphoinositide 3-Kinase δ Syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023t;152:984-96.e10. https://doi.org/10.1016/j.jaci.2023.06.015

Dorsey MJ, Condino-Neto A. Improving access to therapy for patients with inborn errors of immunity: A call to action. J Allergy Clin Immunol Pract. 2023;11:1698-702. https://doi.org/10.1016/j.jaip.2023.04.019

Rao VK, Webster S, Šedivá A, Plebani A, Schuetz C, Shcherbina A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023;141:971-83. https://doi.org/10.1182/blood.2022018546

Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL. PI3Kδ Pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3Kδ syndrome and beyond. J Allergy Clin Immunol Pract. 2024;12:69-78. https://doi.org/10.1016/j.jaip.2023.09.016

Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) Registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract. 2019;7:1763-70. https://doi.org/10.1016/j.jaip.2019.02.004

How to Cite
1.
Fernandes-Pineda M, Zea-Vera AF. Lymphoproliferation and hyper-IgM as the first manifestation of activated phosphoinositide 3-kinase δ syndrome: A case report. Biomed. [Internet]. 2024 Dec. 23 [cited 2026 Jan. 13];44(Sp. 2):10-5. Available from: https://revistabiomedicaorg.biteca.online/index.php/biomedica/article/view/7436

Some similar items:

Published
2024-12-23

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Crossref Cited-by logo
Escanea para compartir
QR Code